A randomized controlled trial of belimumab for the treatment of active systemic lupus erythematosus

Affiliations

Comment

Ryan G Gamble et al. Arch Dermatol. 2012 Mar.

. 2012 Mar;148(3):376-8.

doi: 10.1001/archdermatol.2011.1266.

¹ School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

No abstract available

Comment on

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group. Navarra SV, et al. Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4. Lancet. 2011. PMID: 21296403 Clinical Trial.